IVEVF Articles, Inventiva SA - From 07/18/24

Royalty certificates subscribed by Samsara BioCapital and existing shareholders (BVF Partners, NEA, Sofinnova and Yiheng). Royalty of 3% on futur...

Recruitment in NATiV3 clinical trial continues in both cohorts with over 80% of the targeted number of patients enrolled in the main cohort and 1...

Daix, 21 June 2024  Pursuant to Article 241-2 of the AMF General Regulations (Règlement Général de l'Autorité des marchés financiers), ...

Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company foc...

The first abstract demonstrates that the improvements of MACK-3, a diagnostic test for metabolic dysfunction-associated steatohepatitis, parallel...

Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 20...

The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned r...

Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), ...

Daix (France), Long Island City (New York, United States), April 3, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmaceu...

Daix (France), Long Island City (New York, United States), March 28, 2024 – Inventiva (NASDAQ:IVA) (the "Company"), a clinical-stage biopharmace...